Table 2.

Characteristics of 22 relapsed lung ADC patients with potential squamous transition

Patient ID	Gender	Age	Smoking status	Therapy	1st biopsya		2nd biopsyb		References
					Pathological status	Mutation status	Pathological status	Mutation status
1	F	79	N	Chemotherapy	ADC	EGFR 19 del	SCC	EGFR 19 del	[112]
2	M	43	Y	Chemotherapy	ADC	EGFR 19 del	SCC	EGFR 19 del	[113]
3	F	48	N	Gef	ADC	EGFR 19 del	SCC	EGFR 19 del	[114]
4	F	51	NA	Gef	ADC	EGFR 19 del	SCC	EGFR 19 del	[115]
5	F	58	Y	Erl	ADC	EGFR 19 del	SCC	EGFR 19 del	[116]
6	F	66	N	Erl	ADC	EGFR 19 del	SCC	EGFR 19 del	[117]
7	F	67	NA	Afa	ADC	EGFR 19 del	SCC	EGFR 19 del and PIK3CA mutation	[118]
8	F	40	Y	Afa	ADC	EGFR 19 del	SCC	EGFR 19 del + T790M	[119]
9	F	79	N	Gef	ADC	EGFR 19 del	SCC	EGFR L858R + T790M	[120]
10	M	41	Y	Gef	ADC	EGFR 19 del	SCC + SCLC	NA	[61]
11	F	52	Y	Erl + Beva	ADC	EGFR 19 del	SCC	EGFR 19 del	[121]
12	F	61	N	Gef	ADC	EGFR L858R	SCC	EGFR L858R	[115]
13	M	62	N	Gef	ADC	EGFR L858R	SCC	EGFR L858R	[122]
14	F	63	N	Erl	ADC	EGFR L858R	SCC	EGFR L858R and PIK3CA	[123]
15	F	74	Y	Gef	ADC	EGFR L858R	SCC	EGFR L858R + T790M	[120]
16	M	68	Y	Erl	ADC	EGFR L858R	SCC	EGFR L858R + T790M	[124]
17	F	43	Y	Gef	ADC	EGFR L858R	SCC	EGFR L858R +S768I	[125]
18	F	64	N	Gef	ADC	EGFR L858R + T790M	SCC	EGFR L858R + T790M	[114]
19	F	60	Y	ALK TKI	ADC	ALK	SCC	ALK	[126]
20	F	52	N	Crizo/Alec	ADC	ALK	SCC	ALK	[127]
21	F	63	N	Erl	ADC	WT	SCC	EGFR L858R + T790M	[128]
22	M	69	N	Chemotherapy–immunotherapy	ADC	WT	SCC	NA	[129]

Y yes, N no, NA not available, M male, F female, ADC adenocarcinoma, SCC squamous cell carcinoma, SCLC small cell lung cancer, EGFR epidermal growth factor receptor, TKI tyrosine kinase inhibitor, Gef gefitinib, Erl erlotinib, Afa afatinib, Crizo crizotinib, Alec alectinib, Ceri ceritinib, Beva bevacizumab, ALK anaplastic lymphoma kinase, WT wild type, EGFR 19 del EGFR exon 19 deletion

^a1st biopsy: the first biopsy

^b2nd biopsy: the second biopsy